Reports Q2 revenue $50M, consensus $44.19M. “Castle delivered an outstanding second quarter, with strength across our entire test portfolio,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Building on our first quarter momentum and driven by consistent execution across the entire Castle team, we delivered strong test report volume and revenue growth. Based on strong first half 2023 execution and confidence in our business, we are raising our 2023 revenue guidance to at least $180 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CSTL:
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- Castle Biosciences management to meet with BTIG
- Castle Biosciences director sells $1.02M in common stock
- Castle Biosciences stock up amid ADLT status for DecisionDx-SCC, says KeyBanc
- Castle Bio (NASDAQ:CSTL) Skyrockets after Novitas Drops Key Coverage Proposal